doxepin

(redirected from Silenor)
Also found in: Dictionary, Thesaurus.
Related to Silenor: doxepin

doxepin

 [dok´sĕ-pin]
a tricyclic antidepressant, administered orally as the hydrochloride salt to treat depression, anxiety, chronic pain, peptic ulcer, pruritus, and other conditions.

doxepin

/dox·e·pin/ (dok´sĕ-pin) a tricyclic antidepressant of the dibenzoxepine class; also used to treat chronic pain, peptic ulcer, pruritus, and idiopathic cold urticaria, administered as the hydrochloride salt.

doxepin

(dŏk′sə-pĭn′)
n.
A tricyclic drug, C19H21NO, used in its hydrochloride form orally to treat depression and anxiety and as a cream to relieve itching.

Doxepin®

Zonalon® Pharmacology A tricyclic antidepressant, see there.

doxepin

A TRICYCLIC ANTIDEPRESSANT DRUG. A brand name is Sinequan.

doxepin (topical)

(dok´səpin),
n brand name: Zonolon;
drug class: topical antipruritic (tricyclic antidepressant);
action: antipruritic mechanism unknown; has antihistaminic activity; also produces drowsiness;
uses: pruritus associated with eczema, atopic dermatitis, lichen simplex chronicus.

doxepin

a tricyclic antidepressant and potent histamine H1-receptor blocker, similar to amitriptyline, used in the treatment of psychogenic dermatitis in dogs and cats.
References in periodicals archive ?
The Canadian company said that Silenor (doxepin hydrochloride) is available in 3mg or 6mg oral tablets indicated for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings.
Patients should only take Silenor when they are prepared to get a full night's sleep.
Expenses related to Silenor development work also decreased because a higher level of activity relating to the preparation of the NDA and the conduct of non-clinical studies was ongoing during the first quarter of 2008 compared to the first quarter of 2009.
Pascoe, Somaxon's President and Chief Executive Officer, said, "We believe this acquisition will provide the opportunity to more fully capitalize on the Silenor brand.
TO) said on Monday that it has received approval from Health Canada for Silenor (doxepin hydrochloride) for the treatment and symptomatic relief of insomnia characterised by frequent nocturnal awakening and/or early morning awakenings.
In April 2012, Somaxon entered into a collaboration with CJ CheilJedang Corporation, pursuant to which CJ CheilJedang will commercialize Silenor in South Korea, if approved.
During the meeting, which Somaxon attended together with its partner in the Selenor product, Procter & Gamble (NYSE:PG), the FDA gave its clinical and regulatory guidance that Somaxon will take into account in developing an OTC version of Silenor.
27 August 2010 - US Somaxon Pharmaceuticals Inc (NASDAQ: SOMX) said on Wednesday it has signed a co-promotion agreement with Procter & Gamble (NYSE: PG) for Silenor (doxepin), a newly-approved treatment for insomnia characterised by difficulty with sleep maintenance.
This transaction helps us further our goal of maximizing the value of Silenor for our stockholders by selectively licensing rights to the product outside of the U.
TO) and Somaxon Pharmaceuticals Inc (Nasdaq:SOMX) revealed jointly on Wednesday the acceptance of a New Drug Submission (NDS) for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Somaxon held a meeting with senior leadership at the US Food and Drug Administration (FDA) on 20 January 2010 to discuss the issues raised by the FDA in the Complete Response Letter (CRL) Somaxon received in December 2009 relating to the Silenor NDA.
We will also continue to work with our strategic advisor, Stifel Nicolaus Weisel, to evaluate strategic alternatives with the goal of fully leveraging Silenor for the benefit of our stockholders," continued Mr.